Atlas Trials

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Clinical trial NCT02877082 · TERMINATED

Trial details

NCT number
NCT02877082
Sponsor
Emory University
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveDiffuse Large B-Cell LymphomaFollicular LymphomaGraft Versus Host DiseaseMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic SyndromeMyelofibrosisMyeloproliferative NeoplasmSmall Lymphocytic Lymphoma
Start date
2016-09-01
Primary completion
2017-07-01
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.